Trial Profile
A 26-week, Multicentre, Open-labelled, Non-randomised, Non-interventional, Observational, Safety Study of NovoNorm (Repaglinide) and Insulin Analogue Combination Therapy in Type 2 Diabetes in Korea.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2014
Price :
$35
*
At a glance
- Drugs Repaglinide (Primary) ; Insulin; Metformin; Thiazolidinediones
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 24 Aug 2011 Actual initiation date (Aug 2011) added as reported by ClinicalTrials.gov.